Cargando…
Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Isra...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327654/ https://www.ncbi.nlm.nih.gov/pubmed/22523582 http://dx.doi.org/10.1371/journal.pone.0035298 |
_version_ | 1782229673696034816 |
---|---|
author | Tenenbaum, Alexander Medvedofsky, Diego Fisman, Enrique Z. Bubyr, Liudmila Matetzky, Shlomi Tanne, David Klempfner, Robert Shemesh, Joseph Goldenberg, Ilan |
author_facet | Tenenbaum, Alexander Medvedofsky, Diego Fisman, Enrique Z. Bubyr, Liudmila Matetzky, Shlomi Tanne, David Klempfner, Robert Shemesh, Joseph Goldenberg, Ilan |
author_sort | Tenenbaum, Alexander |
collection | PubMed |
description | BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Israeli Surveys (ACSIS) and were treated on discharge with a fibrate (mainly bezafibrate) and statin combination vs. statin alone. METHODS: The study population comprised 8,982 patients from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment waves who were alive on discharge and received statin. Of these, 8,545 (95%) received statin alone and 437 (5%) received fibrate/statin combination. MACE was defined as a composite measure of death, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke and urgent revascularization. RESULTS: Patients from the combination group were younger (58.1±11.9 vs. 62.9±12.6 years). However, they had significantly more co-morbidities (hypertension, diabetes), current smokers and unfavorable cardio-metabolic profiles (with respect to glucose, total cholesterol, triglyceride and HDL-cholesterol). Development of MACE was recorded in 513 (6.0%) patients from the statin monotherapy group vs. 13 (3.2%) from the combination group, p = 0.01. 30-day re-hospitalization rate was significantly lower in the combination group: 68 (15.6%) vs. 1691 (19.8%) of patients, respectively; p = 0.03. Multivariable analysis identified the fibrate/statin combination as an independent predictor of reduced risk of MACE with odds ratio of 0.54, 95% confidence interval 0.32–0.94. CONCLUSION: A significantly lower risk of 30-day MACE rate was observed in patients receiving combined fibrate/statin treatment following ACS compared with statin monotherapy. However, caution should be exercised in interpreting these findings taking into consideration baseline differences between our observational study groups. |
format | Online Article Text |
id | pubmed-3327654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33276542012-04-20 Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data Tenenbaum, Alexander Medvedofsky, Diego Fisman, Enrique Z. Bubyr, Liudmila Matetzky, Shlomi Tanne, David Klempfner, Robert Shemesh, Joseph Goldenberg, Ilan PLoS One Research Article BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Israeli Surveys (ACSIS) and were treated on discharge with a fibrate (mainly bezafibrate) and statin combination vs. statin alone. METHODS: The study population comprised 8,982 patients from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment waves who were alive on discharge and received statin. Of these, 8,545 (95%) received statin alone and 437 (5%) received fibrate/statin combination. MACE was defined as a composite measure of death, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke and urgent revascularization. RESULTS: Patients from the combination group were younger (58.1±11.9 vs. 62.9±12.6 years). However, they had significantly more co-morbidities (hypertension, diabetes), current smokers and unfavorable cardio-metabolic profiles (with respect to glucose, total cholesterol, triglyceride and HDL-cholesterol). Development of MACE was recorded in 513 (6.0%) patients from the statin monotherapy group vs. 13 (3.2%) from the combination group, p = 0.01. 30-day re-hospitalization rate was significantly lower in the combination group: 68 (15.6%) vs. 1691 (19.8%) of patients, respectively; p = 0.03. Multivariable analysis identified the fibrate/statin combination as an independent predictor of reduced risk of MACE with odds ratio of 0.54, 95% confidence interval 0.32–0.94. CONCLUSION: A significantly lower risk of 30-day MACE rate was observed in patients receiving combined fibrate/statin treatment following ACS compared with statin monotherapy. However, caution should be exercised in interpreting these findings taking into consideration baseline differences between our observational study groups. Public Library of Science 2012-04-16 /pmc/articles/PMC3327654/ /pubmed/22523582 http://dx.doi.org/10.1371/journal.pone.0035298 Text en Tenenbaum et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tenenbaum, Alexander Medvedofsky, Diego Fisman, Enrique Z. Bubyr, Liudmila Matetzky, Shlomi Tanne, David Klempfner, Robert Shemesh, Joseph Goldenberg, Ilan Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title | Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title_full | Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title_fullStr | Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title_full_unstemmed | Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title_short | Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data |
title_sort | cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: acute coronary syndrome israeli surveys data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327654/ https://www.ncbi.nlm.nih.gov/pubmed/22523582 http://dx.doi.org/10.1371/journal.pone.0035298 |
work_keys_str_mv | AT tenenbaumalexander cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT medvedofskydiego cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT fismanenriquez cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT bubyrliudmila cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT matetzkyshlomi cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT tannedavid cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT klempfnerrobert cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT shemeshjoseph cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata AT goldenbergilan cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata |